Top LP award caps off industry-leading
performance across multiple categories at annual Lift Gala
MARKHAM, ON, Dec. 1, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF)
("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP
certified producer of medical cannabis, is proud to announce that
it won a total of 10 prestigious awards – more than any other LP –
at the 2017 edition of the Canadian Cannabis Awards including Top
Licensed Producer.
In addition to Top LP, MedReleaf won a number of other
categories including:
- Top Indica Flower, Sedamen
- Top High CBD Flower, Avidekel
- Top High THC Flower, Eran
Almog
- Top High CBD Oil, Avidekel
"I am incredibly proud of our showing at the Canadian Cannabis
Awards this year. Taking top spot in four categories, in addition
to Top LP, is a testament to the hard work of every single member
of the MedReleaf team and the support of our loyal patient base,"
noted Neil Closner, CEO of
MedReleaf.
MedReleaf rounded out its total of 10 awards with second place
finishes in top customer service, packaging, compassionate pricing
and top hybrid flower for perennial award-winning strain, Midnight.
The Company's Luminarium strain took home third place for top
sativa. Each of the awards received by MedReleaf were in
voter-driven categories.
"Many of this year's winning MedReleaf varieties – Luminarium,
Midnight, Sedamen, Avidekel – have consistently found a place in
the top 3 since the inception of the awards. This is further proof
of the enduring strength of our portfolio and our expertise in
growing a consistently high-quality product," added Closner. "These
awards are voted by patients and provide validation of our
Medical Grade Standards and commitment to excellence."
About MedReleaf Corp.
MedReleaf sets The Medical Grade
Standard™ for cannabis in Canada and
around the world. The first and only ICH-GMP and ISO 9001
certified cannabis producer in North
America, MedReleaf is an R&D-driven company dedicated
to patient care, scientific innovation, research and advancing the
understanding of the therapeutic benefits of cannabis.
Sourced from around the world and carefully cultivated in one of
two state of the art facilities
in Ontario, MedReleaf delivers a variety of premium
products to patients seeking safe, consistent and effective medical
cannabis.
For more information on MedReleaf, its products, research
and how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleaf
Forward Looking Statements
This press release contains
"forward-looking information" within the meaning of applicable
Canadian securities legislation, which can be identified by the use
of forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact. The
forward-looking information contained in this press release are
based upon MedReleaf's current internal expectations,
estimates, projections, assumptions and beliefs and views of future
events which management believes to be reasonable in the
circumstances, including expectations and assumptions regarding the
regulatory environment in Canada. Forward-looking information
are subject to known and unknown risks and uncertainties, including
risks and uncertainties which could cause actual events or results
to differ materially from those described in any forward‑looking
information, including risks and uncertainties relating to general
economic conditions, changes in the regulatory and legal
environments relating to cannabis, competition, counterparty risk,
as well as those risks and uncertainties and other cautionary
statements contained in MedReleaf's Annual Information
Form dated June 27, 2017, which is available electronically
at www.sedar.com. Any forward-looking information contained
herein speaks only as of the date on which it is given and, except
as required by law, MedReleaf does not undertake any
obligation to update or revise any forward‑looking information,
whether as a result of new information, future events or
otherwise.
SOURCE MedReleaf Corp.